Michael P. Curry

9.6k total citations · 1 hit paper
177 papers, 4.3k citations indexed

About

Michael P. Curry is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Michael P. Curry has authored 177 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Hepatology, 111 papers in Epidemiology and 41 papers in Surgery. Recurrent topics in Michael P. Curry's work include Liver Disease Diagnosis and Treatment (96 papers), Hepatitis C virus research (84 papers) and Liver Disease and Transplantation (75 papers). Michael P. Curry is often cited by papers focused on Liver Disease Diagnosis and Treatment (96 papers), Hepatitis C virus research (84 papers) and Liver Disease and Transplantation (75 papers). Michael P. Curry collaborates with scholars based in United States, Ireland and Canada. Michael P. Curry's co-authors include Nezam H. Afdhal, Douglas W. Hanto, John E. Hegarty, James R. Rodrigue, Imad Nasser, Michelle Lai, Benjamin J. Hyatt, Susan McKiernan, Michael Charlton and Niamh Nolan and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Michael P. Curry

167 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome

2021 246 citations Florence Wong, S. Chris Pappas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael P. Curry United States	38	3.3k	2.8k	860	355	347	177	4.3k
Kosh Agarwal United Kingdom	42	8.2k 2.5×	8.2k 3.0×	788 0.9×	423 1.2×	1.2k 3.5×	248	10.0k
Susan L. Orloff United States	32	966 0.3×	1.5k 0.6×	967 1.1×	360 1.0×	138 0.4×	118	2.7k
Elizabeth B. Haagsma Netherlands	37	3.1k 0.9×	1.3k 0.5×	2.3k 2.7×	115 0.3×	390 1.1×	78	4.6k
Martina Sterneck Germany	36	3.2k 1.0×	2.5k 0.9×	1.7k 2.0×	153 0.4×	448 1.3×	165	4.7k
Valentín Cuervas‐Mons Spain	29	1.5k 0.4×	1.2k 0.4×	1.3k 1.5×	88 0.2×	385 1.1×	129	2.8k
Lewis Teperman United States	34	4.7k 1.4×	3.6k 1.3×	3.1k 3.6×	102 0.3×	462 1.3×	98	7.0k
Giorgio Enrico Gerunda Italy	32	2.3k 0.7×	1.8k 0.7×	1.7k 2.0×	55 0.2×	358 1.0×	136	3.7k
Paulo Fontes United States	36	2.3k 0.7×	1.5k 0.5×	2.4k 2.8×	308 0.9×	115 0.3×	100	4.5k
Patricia A. Sheiner United States	38	3.7k 1.1×	2.2k 0.8×	3.0k 3.5×	95 0.3×	367 1.1×	161	5.6k
Gabriel Gondolesi Argentina	34	1.8k 0.5×	879 0.3×	2.4k 2.8×	182 0.5×	198 0.6×	177	4.0k

Countries citing papers authored by Michael P. Curry

Since Specialization

Citations

This map shows the geographic impact of Michael P. Curry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Curry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Curry more than expected).

Fields of papers citing papers by Michael P. Curry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Curry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Curry. The network helps show where Michael P. Curry may publish in the future.

Co-authorship network of co-authors of Michael P. Curry

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Curry. A scholar is included among the top collaborators of Michael P. Curry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Curry. Michael P. Curry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sarwar, Ammar, Imad Nasser, Jeffrey L. Weinstein, et al.. (2025). Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres. European Journal of Nuclear Medicine and Molecular Imaging. 53(2). 876–889. 2 indexed citations

Lobo, Julio, Caitlin Schneider, Samuel Klein, et al.. (2024). Methods and validation of velacur determined fat fraction in patients with MASLD. SHILAP Revista de lepidopterología. 2(2). 100061–100061. 1 indexed citations

Curry, Michael P., et al.. (2024). The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study. International Journal of Hepatology. 2024. 1–9.

Weinberg, Ethan M., Florence Wong, Hugo E. Vargas, et al.. (2023). Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transplantation. 30(4). 347–355. 3 indexed citations

Curry, Michael P., György Baffy, Eric Chak, et al.. (2023). MELD, MELD 3.0, versus Child score to predict mortality after acute variceal hemorrhage: A multicenter US cohort. Hepatology Communications. 7(10). 6 indexed citations

Curry, Michael P., Hugo E. Vargas, Alex S. Befeler, et al.. (2023). Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies. Hepatology Communications. 7(1). e1307–e1307. 22 indexed citations

Mohanty, Arpan, Devika Kapuria, Andrew Canakis, et al.. (2021). Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study. Liver International. 41(8). 1901–1908. 42 indexed citations

Sarwar, Ammar, Jeffrey L. Weinstein, Anuradha S. Shenoy‐Bhangle, et al.. (2021). Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. Journal of Vascular and Interventional Radiology. 32(11). 1560–1568. 14 indexed citations

Avila, Leyla de, Ali A. Weinstein, Michael Estep, et al.. (2019). Cytokine balance is restored as patient‐reported outcomes improve in patients recovering from chronic hepatitis C. Liver International. 39(9). 1631–1640. 8 indexed citations

10.

Flamm, Steven L., Bruce R. Bacon, Michael P. Curry, et al.. (2018). Real‐world use of elbasvir‐grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Alimentary Pharmacology & Therapeutics. 47(11). 1511–1522. 23 indexed citations

11.

Bourlière, Marc, Stuart C. Gordon, Eugene R. Schiff, et al.. (2018). Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. The Lancet. Gastroenterology & hepatology. 3(8). 559–565. 18 indexed citations

12.

Tapper, Elliot B., et al.. (2017). Suboptimal Implementation of Evidence-based Therapy for Acute Variceal Hemorrhage: A Systematic Review of Observational Studies. Clinical Gastroenterology and Hepatology. 15(9). 1373–1381.e7. 12 indexed citations

13.

Curry, Michael P., Elliot B. Tapper, Bruce R. Bacon, et al.. (2017). Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients. Alimentary Pharmacology & Therapeutics. 46(5). 540–548. 30 indexed citations

14.

Terrault, Norah A., Marina Berenguer, Simone I. Strasser, et al.. (2017). International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 101(5). 956–967. 29 indexed citations

15.

Curry, Michael P., Bruce R. Bacon, Doug Dieterich, et al.. (2016). EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF+RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK. Value in Health. 19(3). A312–A313. 3 indexed citations

16.

Mueller, Jessica L., Lindsay Y. King, Tian Gao, et al.. (2014). Poster Session 1: Viral Hepatitis and Liver Transplant. Hepatology. 60. 532A–545A.

17.

Tapper, Elliot B., Vilas Patwardhan, & Michael P. Curry. (2014). Low Yield and Utilization of Confirmatory Testing in a Cohort of Patients with Liver Disease Assessed for Alpha-1 Antitrypsin Deficiency. Digestive Diseases and Sciences. 60(6). 1589–1594. 6 indexed citations

18.

Bleibel, Wissam, Stephen H. Caldwell, Michael P. Curry, & Patrick G. Northup. (2013). Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list. Transplant International. 26(4). 435–442. 25 indexed citations

19.

Coffin, Carla S., Peter G. Stock, Lorna Dove, et al.. (2010). HBV and HIV Coinfection and Liver Transplant. American Journal of Transplantation. 10(5). 1268–1275. 69 indexed citations

20.

Crosbie, Órla, R. Freaney, Malachi J. McKenna, Michael P. Curry, & John E. Hegarty. (1999). Predicting bone loss following orthotopic liver transplantation. Gut. 44(3). 430–434. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact